Physician profile
Jon Ann Esponge
NPI 1609425008
$9,690.45
in general payments reported to CMS, 2019-2025
29 companies · $3,536 in 2025
The $3,536 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $236 · 2023: $2,192 · 2024: $3,727 · 2025: $3,536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,454.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,562.14 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $894.40 | 2023-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $857.28 | 2023-2025 | Spravato, Xarelto |
| Corium, LLC | $856.62 | 2023-2025 | Azstarys, Adlarity |
| Vanda Pharmaceuticals INC. | $738.82 | 2024-2025 | Fanapt |
| Alkermes, INC. | $612.80 | 2023-2025 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $570.53 | 2024-2025 | Qelbree |
| Axsome Therapeutics, INC. | $557.32 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $473.65 | 2024-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $413.70 | 2023-2025 | Rexulti |
| Lundbeck LLC | $395.54 | 2023-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $223.00 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $222.11 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Bayer Healthcare Pharmaceuticals INC. | $186.11 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $167.87 | 2023-2025 | Trintellix |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $152.60 | 2023 | Breztri, Farxiga |
| Idorsia Pharmaceuticals US INC | $150.66 | 2023 | Quviviq |
| Ironshore Pharmaceuticals INC. | $144.18 | 2023-2024 | Jornay Pm |
| Amgen INC. | $122.67 | 2023 | Repatha |
| Noven Pharmaceuticals, INC. | $111.16 | 2024 | Xelstrym |
| Collegium Pharmaceutical, INC. | $56.08 | 2022-2025 | Jornay Pm |
| Almatica Pharma LLC | $48.80 | 2024 | Loreev Xr |
| Biohaven Pharmaceutical Holding Company Ltd. | $43.63 | 2022 | |
| Boston Scientific Corporation | $37.15 | 2023 | Watchman Flx |
| Glaxosmithkline, LLC. | $31.27 | 2023 | Trelegy Ellipta, Shingrix |
| Ultragenyx Pharmaceutical INC. | $16.05 | 2023 | |
| Xeris Pharmaceuticals, INC. | $15.91 | 2022 | |
| Sage Therapeutics, LLC | $15.67 | 2024 | |
| Nestle Healthcare Nutrition INC. | $12.73 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Esponge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.